MSD has now agreed two deals around the $10bn mark in 2025 as it looks to shore up its pipeline with Keytruda’s looming ...

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be ...

BofA Securities, Inc. acted as financial advisor to Merck in this transaction and Gibson Dunn LLP as its legal advisors. Evercore and Goldman Sachs & Co. LLC acted as financial advisors to Cidara and ...

Chief, Digestive Disease Institute, North Shore University Hospital-Long Island Jewish Medical Center, Manhasset, New York; Associate Professor of Medicine, New York University School of Medicine, New ...

A new study has identified potential broad-spectrum antiviral agents that can target multiple families of RNA viruses that continue to pose a significant threat for future pandemics. A new study has ...

Merck ( MRK) to acquire Cidara Therapeutics ( CDTX) for $221.50 per share in cash, for a total transaction value of ...

Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b ...

The once-daily oral drug, a SARS-CoV-2 main protease inhibitor developed by Shionogi, is registered in Japan and Singapore ...

Merck & Co. is buying the developer of an experimental antiviral drug designed to prevent the flu, as the drugmaker aims to ...

b Records were reviewed for 8 strains of novel H1N1 influenza A, including 7 from the table above; 7 of the 8 patients had prior exposure to oseltamivir, either treatment or prophylaxis, and the ninth ...

Data are from https://www.nature.com/articles/s41467-022-31615-7. The ancestral strain was reported as WA1/2020 D614G. Case et al. report EC 50 values. Data are from ...

Merck agreed to pay $9.2 billion to purchase Cidara Therapeutics, looking to cash in on the firm's experimental flu treatment.